Gene: SLC16A8

23539
MCT3|REMP
solute carrier family 16 member 8
protein-coding
22q13.1
Ensembl:ENSG00000100156 MIM:610409 Vega:OTTHUMG00000151196 UniprotKB:O95907
NC_000022.11
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
2.338e-1 (AD)  2.062e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
LIPE0.775
PTPDC10.774
HAPLN20.762
PDE6B0.73
ABCA20.726
GREB1L0.717
GPR620.713
CNTN20.7
TMEM1250.7
SEMA6A0.699

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MTRNR2L6-0.32
MTRNR2L9-0.313
DIO2-0.307
MTRNR2L10-0.299
EREG-0.296
HGF-0.292
LYN-0.292
ARHGAP42-0.285
C4orf19-0.279
MTRNR2L8-0.277

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00119Pyruvic acidSmall Molecule127-17-3Approved|Investigational|NutraceuticalTarget
ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SLC16A8 mRNA"25510870
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SLC16A8 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SLC16A8 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SLC16A8 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SLC16A8 mRNA"25510870
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in increased expression of SLC16A8 mRNA"18648102
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A8 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A8 mRNA"27188386
D000643Ammonium ChlorideAmmonium Chloride affects the expression of SLC16A8 mRNA16483693
D001280AtrazineAtrazine results in increased expression of SLC16A8 mRNA22378314
C006780bisphenol Abisphenol A results in decreased expression of SLC16A8 mRNA25181051
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of SLC16A8 gene20938992
D003042CocaineCocaine results in decreased expression of SLC16A8 mRNA27899881
D003471CuprizoneCuprizone results in increased expression of SLC16A8 mRNA26577399
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of SLC16A8 mRNA21266533
D002945CisplatinCisplatin results in decreased expression of SLC16A8 mRNA27392435
D004026DieldrinDieldrin results in decreased expression of SLC16A8 mRNA20584760
D000431EthanolEthanol affects the expression of SLC16A8 mRNA24355176
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of SLC16A8 mRNA15576828
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of SLC16A8 gene20938992
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of SLC16A8 gene20938992
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of SLC16A8 mRNA26011545
D010126Ozone"[Water Pollutants, Chemical co-treated with Ozone] results in increased expression of SLC16A8 mRNA"23246600
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SLC16A8 mRNA"25510870
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of SLC16A8 mRNA19710929
D010936Plant ExtractsPlant Extracts results in decreased expression of SLC16A8 mRNA23557933
D059808PolyphenolsPolyphenols results in decreased expression of SLC16A8 mRNA16293270
D011192Potassium DichromatePotassium Dichromate results in increased expression of SLC16A8 mRNA23608068
C009277sodium arsenatesodium arsenate results in increased expression of SLC16A8 mRNA23922661
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of SLC16A8 mRNA21570461
D014635Valproic AcidValproic Acid results in increased methylation of SLC16A8 gene29154799
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A8 mRNA"27188386
D014874Water Pollutants, Chemical"[Water Pollutants, Chemical co-treated with Ozone] results in increased expression of SLC16A8 mRNA"23246600

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005215transporter activity-IBA21873635  
GO:0008028monocarboxylic acid transmembrane transporter activity-IBA21873635  
GO:0008028monocarboxylic acid transmembrane transporter activity-TAS-  
GO:0015129lactate transmembrane transporter activity-EXP15917240  
GO:0015293symporter activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006090pyruvate metabolic process-TAS-  
GO:0015718monocarboxylic acid transport-IBA21873635  
GO:0015727lactate transport-TAS10493836  
GO:0035873lactate transmembrane transport-IEA-  
GO:0050900leukocyte migration-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-IBA21873635  
GO:0005887integral component of plasma membrane-IEA-  
GO:0016020membrane-TAS10493836  
GO:0016021integral component of membrane-IBA21873635  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-109582HemostasisTAS
R-HSA-1428517The citric acid (TCA) cycle and respiratory electron transportTAS
R-HSA-1430728MetabolismTAS
R-HSA-202733Cell surface interactions at the vascular wallTAS
R-HSA-210991Basigin interactionsTAS
R-HSA-382551Transport of small moleculesTAS
R-HSA-425366Transport of bile salts and organic acids, metal ions and amine compoundsTAS
R-HSA-425407SLC-mediated transmembrane transportTAS
R-HSA-433692Proton-coupled monocarboxylate transportTAS
R-HSA-70268Pyruvate metabolismTAS
R-HSA-71406Pyruvate metabolism and Citric Acid (TCA) cycleTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
29487693Uncovering genetic and non-genetic biomarkers specific for exudative age-related macular degeneration: significant association of twelve variants. (2018 Jan 30)Cascella ROncotarget